Skip to content
DataLookout
Menu

NCT06176118

Clinical Trial of 2-HOBA in Pulmonary Arterial Hypertension

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary completion moved at least 4 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 9 versions: 9 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Start date: Sep 1, 2026 to May 1, 2027
    • Eligibility criteria expanded, about 17 words
    • Primary and study completion pushed from Dec 2027 to May 2028
    • Secondary endpoints: details revised at 4 of 7 entries
  2. Notable Primary and study completion dates pushed to Dec 2027
    • Start date: May 1, 2026 to Sep 1, 2026
    v8
  3. Notable Start date: Dec 1, 2025 to May 1, 2026
    • Primary completion date: Aug 2026 to Dec 2026
    v7
  4. Notable Start date: May 1, 2025 to Dec 1, 2025v6
  5. Notable Start date: Aug 1, 2024 to May 1, 2025
    • Primary completion date: Apr 2026 to Aug 2026
    • Study completion date: Jul 2026 to Jul 2027
    v5
Show 3 earlier versionsHide 3 earlier versions
  1. Notable Start date: May 1, 2024 to Aug 1, 2024v4
  2. Notable Start date: Mar 15, 2024 to May 1, 2024v3
  3. Notable Start date: Jan 1, 2024 to Mar 15, 2024v2
  1. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Change in acetylated SOD2 and LCAD in plasma
Timeframe: baseline and 12-weeks

Secondary (7)

Change in plasma LDL, HDL, triglyceride, free fatty acid concentration measured as a concentration (mg/dL)
Change in plasma acylcarnitine profile measured as a concentration (mg/dL)
Change in meters walked in six-minute walk distance (meters)
Change in Quality of Life as measured by the emPHasis-10
Change in Estimated Right Ventricle (RV) Systolic Pressure, as assessed by echocardiogram results, expressed in mmHg
Show 2 moreShow less
Change in Right Ventricle (RV) Free Wall Longitudinal Strain, as assessed by echocardiogram results, and expressed as percent (%) change in myocardial deformation.
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

Arms and interventions

Unblinded InterventionExperimental

There is no control group in this study. Only intervention group due to phase of trial and study intentions.

Dietary supplements: 2-HOBA